Qiagen N.V.
Case Overview
| Status: | Status: Investigating |
| Company Name: | Company Name: Qiagen N.V. |
| Ticker: | Ticker: QGEN |
| Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
| Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP is investigating potential claims against Qiagen N.V. (“Qiagen” or the “Company”) (NYSE:QGEN). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.
On February 5, 2026, Qiagen released fourth quarter 2025 earnings and stated that QuantiFERON would accelerate to achieve “between 6% and 7% growth” in 2026.
On April 27, 2026, Qiagen announced preliminary results for the first quarter of 2026. Among other things, the Company disclosed that net sales declined approximately 1% on a constant exchange rate (“CER”) basis, and that sales of its QuantiFERON product declined approximately 5% CER. On this news, the price of Qiagen shares declined by $4.07 per share, or approximately 11%, from $38.09 per share on April 27, 2026 to close at $34.02 on April 28, 2026.
On February 5, 2026, Qiagen released fourth quarter 2025 earnings and stated that QuantiFERON would accelerate to achieve “between 6% and 7% growth” in 2026.
On April 27, 2026, Qiagen announced preliminary results for the first quarter of 2026. Among other things, the Company disclosed that net sales declined approximately 1% on a constant exchange rate (“CER”) basis, and that sales of its QuantiFERON product declined approximately 5% CER. On this news, the price of Qiagen shares declined by $4.07 per share, or approximately 11%, from $38.09 per share on April 27, 2026 to close at $34.02 on April 28, 2026.